| __timestamp | CRISPR Therapeutics AG | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 305409000 |
| Thursday, January 1, 2015 | 13403000 | 377080000 |
| Friday, January 1, 2016 | 31056000 | 432829000 |
| Sunday, January 1, 2017 | 35845000 | 496079000 |
| Monday, January 1, 2018 | 48294000 | 557616000 |
| Tuesday, January 1, 2019 | 63488000 | 658498000 |
| Wednesday, January 1, 2020 | 88208000 | 770456000 |
| Friday, January 1, 2021 | 102802000 | 840100000 |
| Saturday, January 1, 2022 | 102464000 | 944700000 |
| Sunday, January 1, 2023 | 76162000 | 1136600000 |
| Monday, January 1, 2024 | 72977000 | 1464300000 |
Unleashing insights
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG, two giants in the field, have shown contrasting trends in their SG&A management from 2014 to 2023.
Vertex Pharmaceuticals has consistently maintained higher SG&A expenses, peaking at approximately $1.14 billion in 2023, reflecting a 272% increase from 2014. This trend suggests a robust investment in administrative and sales functions, potentially driving their market dominance. In contrast, CRISPR Therapeutics AG, with a more conservative approach, saw their SG&A expenses rise by about 1,389% over the same period, reaching around $76 million in 2023.
While Vertex's higher expenses might indicate aggressive expansion, CRISPR's leaner approach could suggest a focus on cost efficiency. Understanding these strategies offers valuable insights into their operational priorities and market strategies.
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.